Transplantation is a surgical procedure that involves the replacement of damaged or failed cell, tissue, or organ from one site to other site of the same individual or different individual of same or different species. Transplantation procedures require diagnostics tests to check HLA and rejection monitoring. Transplantation diagnostics are diagnostic tests the detect HLA compatibility between the donor and recipient prior to transplantation procedures and monitors transplanted organs post-surgery for rejection. According to the estimation of National Kidney Foundation in the US, around 17,107 transplants took place in 2014 and over 3,000 patients are added to the waiting list for kidney every month. According to the Canadian Transplant Society, every year approximately 1,600 Canadians are added to the graft wait list annually. Around 90% of the people support transplantation of which only 20% plan to donate organs. Increasing transplantation cases and the growing awareness toward transplantation in public are expected to fuel the growth of the transplantation diagnostics market in the near future.
The transplantation diagnostics market is booming due to the growing patient base for chronic disease globally, growing elderly population, and the increasing number of organ transplantation procedures. High cost of sequencing instrument, requirement of skilled labors, and the difference between organs donated and patients waiting for transplantation are some of the factors hampering the market growth. The market in emerging countries is expected to grow at a rapid pace during the forecast period due the increasing healthcare awareness among public, growing patient pool, and the increasing healthcare spending.
The “Global Transplantation Diagnostics Market” is estimated to witness a CAGR of 10.9% during the forecast period 2017–2023. The market is analyzed based on six segments, namely technology, products, screening methods, application, end-users, and regions.
The regions covered in the report are North America, Europe, Asia Pacific, and Rest of the World (RoW). North America is set to be the leading region for the transplantation diagnostics market growth followed by Europe. Asia Pacific and RoW are set to be the emerging regions.
The global transplantation diagnostics market by technology is segmented into molecular assays and non-molecular assays. Molecular assays include PCR-based and sequencing-based assays. Molecular assays occupy the largest share in 2016 due to its better sensitivity, specificity, and high resolving power.
The global transplantation diagnostics market by product type is segmented into instruments, consumables & reagents, and softwares and services. Reagents and consumables occupy the major market share in 2016 due to repeat purchase of the consumables and reagents to perform the tests.
Screening Method Analysis
The global transplantation diagnostics market by screening method is segmented into pre-transplantation screening and post-transplantation screening. Post-transplantation screening occupies the major market share in 2016.
The global transplantation diagnostics market by application is segmented into diagnostic and research applications. Diagnostic application occupies the largest market share and is expected to be the fastest growing segment during the forecast period.
The global transplantation diagnostics market by end-users is segmented into hospital & transplant centers, commercial service providers, and academics and research laboratories. Hospital and transplant centers occupy a major share of transplantation diagnostics market in 2016 due to an increase in surgical procedures.
Thermo Fisher Scientific, Inc., Illumina, Inc., Bio-Rad Laboratories, Inc., Immucor, Inc., CareDx, Inc., Abbott Laboratories, Qiagen N.V., bioMerieux S.A., F. Hoffmann-La Roche, Omixon Ltd, and other predominate & niche players.
Currently, the diagnostic assays based on molecular method dominates the global transplantation diagnostics market. A lot of new players are concentrating on this market to provide innovative tests to detect acute rejection within few weeks of transplantation with high sensitivity and specificity. The key market players are acquiring small companies to enhance their product portfolio and strengthen their leadership position in the market. Apart from this, major players are launching innovative tests to have an edge in the market. For instance, in February 2017, Immucor Inc. launched MIA FORA NGS FLEX HLA Typing Assay that provides comprehensive coverage of up to 11 HLA genes. The company also launched molecular gene expression assay, kidney Solid Organ Response Test (kSORT), to predict organ rejection and graft injury in May 2016.
The report provides complete details about the usage and adoption rate of transplantation diagnostics products in various applications and regions. With that, the key stakeholders can know about the major trends, drivers, investments, vertical player’s initiatives, and government initiatives toward test adoption in the upcoming years along with the details of commercial tests available in the market. Moreover, the report provides details about the major challenges that are going to impact on the market growth. Additionally, the report gives complete details about the key business opportunities to key stakeholders to expand their business and capture the revenue in the specific verticals to analyze before investing or expanding the business in this market.